Switching from omalizumab to mepolizumab: real-life experience from Southern Italy

BACKGROUND: Current availability of several biologic treatments for severe asthma makes it possible to choose the most appropriate for each patient. Sometimes a good percentage of patients with severe asthma may be eligible for biologics that target either the allergic phenotype or the eosinophilic...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ther Adv Respir Dis
Autors principals: Carpagnano, Giovanna Elisiana, Pelaia, Corrado, D’Amato, Maria, Crimi, Nunzio, Scichilone, Nicola, Scioscia, Giulia, Resta, Onofrio, Calabrese, Cecilia, Pelaia, Girolamo, Quarato, Carla Maria Irene, Foschino Barbaro, Maria Pia
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7268123/
https://ncbi.nlm.nih.gov/pubmed/32482128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466620929231
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars